Overexpression of human epidermal growth factor receptor 2 in canine primary          lung cancer

Sho YOSHIMOTO; Daiki KATO; Satoshi KAMOTO; Kie YAMAMOTO; Masaya TSUBOI; Masahiro SHINADA; Namiko IKEDA; Yuiko TANAKA; Ryohei YOSHITAKE; Shotaro ETO; Kohei SAEKI; James CHAMBERS; Yuko HASHIMOTO; Kazuyuki UCHIDA; Ryohei NISHIMURA; Takayuki NAKAGAWA

doi:10.1292/jvms.20-0026

Surgery

Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer

Sho YOSHIMOTO, Daiki KATO, Satoshi KAMOTO, Kie YAMAMOTO, Masaya TSUBOI, Masahiro SHINADA, Namiko IKEDA, Yuiko TANAKA, Ryohei YOSHITAKE, Shotaro ETO, Kohei SAEKI, James CHAMBERS, Yuko HASHIMOTO, Kazuyuki UCHIDA, Ryohei NISHIMURA, Takayuki NAKAGAWA

著者情報

Sho YOSHIMOTO
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Daiki KATO
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Satoshi KAMOTO
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Kie YAMAMOTO
Veterinary Medical Center, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Masaya TSUBOI
Veterinary Medical Center, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Masahiro SHINADA
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Namiko IKEDA
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Yuiko TANAKA
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Ryohei YOSHITAKE
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Shotaro ETO
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Kohei SAEKI
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
James CHAMBERS
Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Yuko HASHIMOTO
Veterinary Medical Center, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Kazuyuki UCHIDA
Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Ryohei NISHIMURA
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Takayuki NAKAGAWA
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

キーワード: Canis familiaris, lung cancer, oncogene protein human epidermal growth factor receptor 2

ジャーナルオープンアクセス
電子付録

2020 年 82 巻 6 号 p. 804-808

DOI https://doi.org/10.1292/jvms.20-0026

Browse “Advance online publication” version

詳細

抄録

Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic therapies for dogs with late-stage cPLC. HER2-targeted therapy could be an option for cPLC, but HER2 expression in cPLC remains unknown. We evaluated HER2 expression in cPLC. Immunohistochemical analysis revealed that 3 samples (19%) scored 3+; 8 (50%), 2+; 5 (31%); and 1+ and 0 (0%), 0. Of the cPLC tissues, 69% were HER2 positive (scored ≥2+). These data would lead to further evaluation of the role of HER2 in cPLC as a mechanism of malignancy and therapeutic target.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）